Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

Treatment strategies in mucous membrane pemphigoid

Authors Ann G Neff, Matthew Turner, Diya F Mutasim

Published 6 June 2008 Volume 2008:4(3) Pages 617—626

DOI https://doi.org/10.2147/TCRM.S1140

Ann G Neff, Matthew Turner, Diya F Mutasim

Department of Dermatology, University of Cincinnati, Cincinnati, OH, USA

Abstract: Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder that is characterized by subepithelial bullae. Various basement membrane zone components have been identified as targets of autoantibodies in MMP. Considerable variability exists in the clinical presentation of MMP. Mucous membranes that may be involved include the oral cavity, conjunctiva, nasopharynx, larynx, esophagus, genitourinary tract, and anus. A multidisciplinary approach is essential in the management of MMP. Early recognition of this disorder and treatment may decrease disease-related complications. The choice of agents for treatment of MMP is based upon the sites of involvement, clinical severity, and disease progression. For more severe disease, or with rapid progression, systemic corticosteroids are the agents of choice for initial treatment, combined with steroid-sparing agents for long-term maintenance. Due to the rarity of this disease, large controlled studies comparing the efficacy of various agents are lacking.

Keywords: mucous membrane pemphigoid, cicatricial pemphigoid

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Deng L, Ke X, He Z, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J

International Journal of Nanomedicine 2012, 7:5053-5065

Published Date: 19 September 2012

Biofunctionalization of a titanium surface with a nano-sawtooth structure regulates the behavior of rat bone marrow mesenchymal stem cells

Zhang WJ, Li ZH, Liu Y, Ye DX, Li JH, Xu LY, Wei B, Zhang XL, Liu XY, Jiang XQ

International Journal of Nanomedicine 2012, 7:4459-4472

Published Date: 13 August 2012

Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability

Luo H, Jiang B, Li B, Li Z, Jiang BH, Chen YC

International Journal of Nanomedicine 2012, 7:3951-3959

Published Date: 24 July 2012

Percutaneous coronary intervention of a single coronary artery arising from the right sinus of Valsalva

Mehmet Akif Cakar, Ersan Tatli, Bilhan Ozalp, et al

Vascular Health and Risk Management 2010, 6:1077-1078

Published Date: 25 November 2010

The diagnostic value of endothelial function as a potential sensor of fatigue in health

Yoshiko Ohno, Teruto Hashiguchi, Ryuichi Maenosono, et al

Vascular Health and Risk Management 2010, 6:135-144

Published Date: 9 March 2010

Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria

Elmir Omerovic, Gerhard Brohall, Markus Müller, Truls Råmunddal, Göran Matejka, et al

Therapeutics and Clinical Risk Management 2008, 4:705-711

Published Date: 8 August 2008

Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents

Mariagrazia Di Marco, Claudia Sadun, Marc Port, Irene Guilbert, Patrick Couvreur

International Journal of Nanomedicine 2007, 2:609-622

Published Date: 15 January 2008

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008

The renaissance of fixed dose combinations: Combivir

Simon D Portsmouth, Christopher J Scott

Therapeutics and Clinical Risk Management 2007, 3:579-583

Published Date: 15 September 2007